+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lymphoma Drugs Market Research Reports

From
From
Follicular Lymphoma - Pipeline Insight, 2020 - Product Thumbnail Image

Follicular Lymphoma - Pipeline Insight, 2020

  • Drug Pipelines
  • September 2020
  • 120 pages
From
From
From
From
From
From
From
From
From
From
From
Lymphoma Treatment Drugs Companies in China - Product Thumbnail Image

Lymphoma Treatment Drugs Companies in China

  • Report
  • September 2020
  • 71 pages
From
Lymphoma Treatment Drugs Markets in China - Product Thumbnail Image

Lymphoma Treatment Drugs Markets in China

  • Report
  • September 2020
  • 206 pages
From
From
From
From
From
Loading Indicator

Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more

adroll